Quick Facts: Main Therapeutic Domains

• May help address nausea and vomiting.
• Assists in managing dizziness associated with motion.
• Used to manage symptoms of motion sickness and vertigo.

---

What DA Cyclizine HCl Treats: Main Uses and Benefits

DA Cyclizine HCl is a medicinal compound used to assist in the management and prevention of certain symptoms. Its primary use is in the therapeutic domain of preventing and treating nausea and vomiting that may be caused by various conditions.

The medication is often utilized to help manage motion sickness, an issue arising from disturbances in the inner ear's balance system. It may also provide relief for dizziness and symptoms associated with vertigo. Furthermore, healthcare providers may use Cyclizine to address sickness that develops following general anesthesia after surgical procedures.

Cyclizine has established therapeutic applications for specific indications and uses. It is a therapy available to help patients maintain comfort and stability during periods of disequilibrium or gastric distress.

Who can and cannot use DA Cyclizine HCl?

The population eligibility for using DA Cyclizine HCl is defined by official regulatory documents, establishing absolute prohibitions and specific restrictions based on age, pre-existing conditions, and physiological state.

---

Contraindicated Populations

The medicine is contraindicated (must not be used) in:

• Patients with a known hypersensitivity to cyclizine, other piperazine derivatives, or any of the product's excipients.
• Infants and children under 2 years of age.

---

Populations Requiring Restricted or Conditional Use

Use is not recommended or requires caution in several specific groups:

Category	Regulatory Status	Status Detail
Pediatric Use	Not Recommended	Children under 6 years (oral tablet formulations).
Pregnancy/Lactation	Not Recommended	Generally not advised during lactation and use in the first trimester of pregnancy.
Organ Impairment	Use with Caution	Patients with hepatic impairment and renal impairment.
Comorbidities	Use with Caution	Patients with conditions susceptible to anticholinergic effects, such as angle-closure glaucoma, prostatic hypertrophy, epilepsy, and severe cardiac failure.

Interactions with other medicines and products — official regulatory information for DA Cyclizine HCl

Interaction Scope

Category	Official Regulatory Documentation
Medicinal product categories with documented interactions:	Central Nervous System ( CNS) Depressants, Anticholinergic Drugs, Ototoxic Drugs, Opioid Analgesics.
Specific interacting medicines (if explicitly listed):	Pethidine, Alcohol (Ethanol).
Mechanistic basis of interactions (only if stated in label):	Primarily pharmacodynamic additive effects and masking effects.
Timing-based interaction rules (if applicable):	None explicitly stated as mandatory separation rules in official labeling.
Population-specific interaction notes (if applicable):	Patients with hepatic impairment may have a greater risk for adverse effects due to drug accumulation.
Interaction-related restrictions:	Formal contraindication with acute alcohol intoxication.

---

Interaction Classifications (High-Level)

Classification	Official Regulatory Documentation
Interaction severity classification (as defined in official documents):	Contraindicated (for acute alcohol intoxication); Additive Effects (for CNS Depressants, Anticholinergics).
Regulatory basis:	European Medicines Agency ( EMA)/ SmPC, Medsafe, FDA Guidance.
Interaction-context constraints:	Prohibition is required in the presence of acute alcohol intoxication.

---

Resulting Interaction Structure

Official interaction statements:

• Co-administration with CNS Depressants (including hypnotics and antipsychotics) may result in additive effects leading to increased CNS depression.
• Use with Anticholinergic Drugs (such as tricyclic antidepressants) may enhance the side-effects and create an additive antimuscarinic action.
• The anti-emetic action may mask the warning signs of damage caused by Ototoxic Drugs.
• The opioid analgesic Pethidine has a formally documented interaction where co-administration enhances its sedating effect.
• The combination with alcohol is contraindicated in cases of acute alcohol intoxication because the anti-emetic properties may increase the toxicity of alcohol.

Connection to the overall interaction profile (2–4 sentences): The regulatory documents define the interaction structure of Cyclizine HCl as primarily centered on the risk of pharmacodynamic intensification. The profile describes additive effects on the central nervous and anticholinergic systems, necessitating caution for these product classes. The most stringent restriction is the formal contraindication documented for co-exposure with acute alcohol intoxication.

Blocking Histamine Receptor Signals

This mechanism acts primarily by binding to and blocking H1 histamine receptors in the central nervous system. This antagonistic action suppresses the excitatory signals mediated by histamine, thereby reducing the nerve activity that contributes to the sickness reflex pathway.

Modulating the Central Sickness Pathways

The mechanism influences the Brainstem Vomiting Center and the Chemoreceptor Trigger Zone (CTZ), which are the main areas in the brain that coordinate the sickness reflex. By dampening the sensitivity and activity of these critical central control centers, the mechanism decreases the excitability of these centers, which reduces efferent signaling toward the reflex pathways.

Influencing Input from the Balance System

The drug's action extends to the vestibular pathway, which transmits signals related to motion and balance from the inner ear. Blocking the H1 receptors on these nerves modifies the transmission of nerve impulses from the inner ear to the brain, influencing the signal ratio transmitted to the central processing centers within the body's motion-sensing apparatus.

Official Routes and Dosing

Cyclizine hydrochloride is administered via the oral route using the tablet form, or parenterally (usually as the lactate salt) via the intravenous (IV) and intramuscular (IM) routes for acute situations or when oral intake is not possible.

For adults, the standard single oral dose is 50 mg. This dose may be repeated up to three times daily (TDS). The maximum oral quantity is 200 mg in any 24-hour period, with doses spaced by a minimum interval of 4 to 8 hours. When used preventatively, such as for motion sickness, the initial 50 mg oral dose is typically administered one to two hours before the activity is set to begin.

---

Administration Conditions and Age-Specific Rules

Administration instructions define the usage for specific populations and routes. The oral tablet may be taken with or without food. For pediatric use, children aged 6 to 12 years have a lower defined dose of 25 mg, which is administered up to three times daily, with a maximum daily limit of 75 mg. Use in children under 6 years is not generally recommended.

For the parenteral route, the injection is administered slowly, over a minimum period of three minutes, and is intended for acute requirements rather than long-term therapy. Furthermore, if a central venous line is used, it is flushed before and after administration to maintain the integrity of the line.

Research evidence / Overview of studies for DA Cyclizine HCl

---

Evidence for use in Motion Sickness

Research exploring short-term symptom changes related to motion sickness has a long history, as Cyclizine HCl was studied for this use since its initial evaluation. The evidence base includes older clinical trials and regulatory documentation that describe the evaluation of Cyclizine HCl related to the symptoms of nausea, vomiting, and dizziness associated with motion. These studies examined outcomes related to the measured presence or absence of nausea and vomiting, and recorded changes in dizziness or feelings of functional imbalance during periods of movement.

What remains uncertain is that the evidence for this specific use relies heavily on historical data. There is a recognized lack of recent, large-scale Randomized Controlled Trials (RCTs) using the contemporary, standardized assessment methods common in research today.

---

Evidence for use in Postoperative Nausea and Vomiting (PONV)

The evidence base for Cyclizine HCl in the period immediately following surgery includes a higher volume of structured trials. This use has been evaluated in numerous RCTs and is the subject of several meta-analyses in scientific literature, involving various surgical patient cohorts. Studies explored acute symptom changes, typically within the first 24 hours after surgery and general anesthesia.

Research examined outcomes such as the incidence (occurrence) of nausea and the incidence of vomiting post-surgery. These trials also monitored the need for additional anti-sickness medication, known as rescue antiemetics, during the defined observation interval. Studies reported measurements of outcomes related to nausea and vomiting occurrence, and monitored the patterns observed in groups receiving Cyclizine HCl versus established comparison groups.

---

What is Still Uncertain About Cyclizine HCl Evidence

The broader research landscape highlights key areas where certainty remains low or where more research is ongoing. Evidence quality varies across studies, with some indications relying on historical data, while others are supported by structured RCTs. Furthermore, because Cyclizine HCl is often used in multimodal antiemetic protocols for drug-induced sickness, isolating its specific contribution to the outcomes observed can be challenging. Results apply only to the populations studied and do not determine whether an individual will respond similarly.

Key Studies & References WHO Model List of Essential Medicines (Essential Medicine Status for Global Context)

Common questions about DA Cyclizine HCl (FAQ)

---

Q: How quickly can I expect DA Cyclizine HCl to start working?

Official documents indicate that the oral form of cyclizine begins to take effect relatively quickly, usually within 30 minutes of administration. The maximum concentration in the body is typically achieved within one to two hours.

Q: How long does the effect of DA Cyclizine HCl usually last?

The duration of the antiemetic effect for a single oral dose is generally documented in regulatory information to be around 4 to 6 hours. This is the approximate period during which the medicine is active in the body.

Q: Can DA Cyclizine HCl be taken with other cold or allergy medicines?

The official product information warns against combining this medicine with other Central Nervous System (CNS) depressants and certain Anticholinergic drugs. Because some over-the-counter cold and allergy medicines contain these types of ingredients, combining them could intensify side effects such as drowsiness and dry mouth.

Q: What information is available about DA Cyclizine HCl use during pregnancy?

Regulatory documents generally do not advise the use of cyclizine during pregnancy, particularly in the first trimester, due to a lack of complete safety data. The use of the medicine later in pregnancy requires a specific clinical decision based on the potential benefits versus the known risks.

Q: Do any official sources mention a risk of dependence with DA Cyclizine HCl?

Official sources mention that there is a documented abuse potential associated with the use of cyclizine, especially when taken in high doses or over long periods. This warning is present in the official regulatory literature.

Q: Can DA Cyclizine HCl affect your sleep?

As a medicine that affects the Central Nervous System (CNS), drowsiness is a common and expected side effect. This sedation may lead to interference with normal sleep patterns.

Q: Can DA Cyclizine HCl be taken by people with kidney issues?

The official product label indicates that caution is required when this medicine is used by patients with renal impairment (kidney issues). This is a warning because reduced kidney function may affect how the body clears the drug.

Q: Is DA Cyclizine HCl available without a prescription in some countries?

Cyclizine’s availability differs by country; it is legally sold for over-the-counter (OTC) use in certain regions. However, the higher-strength or injectable forms used in hospitals usually require a prescription.

Q: Does DA Cyclizine HCl help with all types of nausea, or just motion sickness?

Official documents indicate that cyclizine is approved for treating more than just motion sickness. It is also used for nausea and vomiting related to post-operative recovery following anesthesia, radiotherapy, and symptoms associated with vertigo.

Q: Can DA Cyclizine HCl be used long-term?

Regulatory guidelines define doses for managing acute, short-term symptoms like motion sickness or temporary nausea. Long-term continuous use of the oral form is not typically established in the official product information.

Q: What is the difference between cyclizine and DA Cyclizine HCl?

Cyclizine is the active medicinal component. The letters HCl stand for hydrochloride, which is a chemical salt form added to the cyclizine base. This salt form helps stabilize the medicine and makes it suitable for absorption.

Q: Are there any common foods or drinks that should be avoided when taking DA Cyclizine HCl?

Regulatory documents do not specify avoiding any common foods when taking this medicine. The key restriction is with alcohol, as it is formally contraindicated in cases of acute intoxication due to the dangerous risk of enhanced side effects.

Q: Can older people or seniors typically use DA Cyclizine HCl?

The official label notes that older adults may be more sensitive to the medicine's effects. They may be more likely to experience side effects affecting the Central Nervous System (CNS), such as drowsiness, and anticholinergic effects like dry mouth.

Q: What is the typical age limit for giving DA Cyclizine HCl to children?

Official guidelines state that the oral tablet formulation is not recommended for children under 6 years of age. The defined pediatric dosing instructions begin for children in the 6 to 12 years age bracket.

Q: Why is DA Cyclizine HCl sometimes mentioned in the context of hospital use?

The medicine is often used in hospitals because it is indicated for Post-Operative Nausea and Vomiting (PONV). It is also available in non-oral forms, such as intravenous (IV) and intramuscular (IM) injections, which are intended for patients who cannot tolerate oral administration.

Q: Is it safe to drive or operate machinery after taking DA Cyclizine HCl?

Regulatory warnings emphasize that this medicine can cause side effects like drowsiness and dizziness. Due to these effects, the official information advises caution when driving a motor vehicle or operating machinery.

Q: Why are people often told not to drink alcohol with DA Cyclizine HCl?

The core warning against combining the medicine with alcohol is due to a risk of additive effects, where the resulting drowsiness and Central Nervous System (CNS) depression are greatly intensified. This combination is formally contraindicated when a person is acutely intoxicated.

Q: Is it common to feel a little dizzy when taking DA Cyclizine HCl?

While cyclizine is used to treat dizziness, official documents also list dizziness as a potential side effect. However, it is generally categorized as uncommon (meaning it does not affect many people) in regulatory documents.

Q: Is there a maximum number of days DA Cyclizine HCl is recommended to be used continuously?

The dosing and indications provided in official documents are established for managing acute and short-term symptoms. While a maximum daily dose is defined, the regulatory label does not specify a precise maximum number of days for continuous oral use.

Q: Are there specific patient populations where side effects are more likely with DA Cyclizine HCl?

Official safety warnings identify several patient groups who may be more at risk for adverse effects. These include older adults and those with pre-existing conditions such as glaucoma, certain prostate issues, or hepatic impairment (liver problems).

Q: Are there any studies comparing DA Cyclizine HCl to a placebo?

Studies supporting the use of cyclizine have been conducted in the form of clinical trials. These trials often compare the effects of the medicine against other treatments or a comparison group, which historically may have involved a placebo (an inactive substance).

Q: Is it true that DA Cyclizine HCl is often used by travelers or sailors?

Yes, it is common for travelers and sailors to use cyclizine. Official documents confirm its use for the prevention and treatment of motion sickness, which makes it a relevant option for managing nausea and vomiting during travel.

Q: What are the different strengths of DA Cyclizine HCl tablets available?

The most widely available tablet strength of cyclizine is 50 mg. Lower doses, such as the 25 mg dose used for children, are sometimes achieved by scoring the 50 mg tablet or available as a separate strength.

Q: Is DA Cyclizine HCl approved for treating post-operative nausea?

Yes, the medicine is formally approved for the prevention and treatment of nausea and vomiting, specifically including that which occurs after a patient receives general anesthetics or narcotic pain relievers in the period following surgery.

Q: Can DA Cyclizine HCl make you constipated?

Official adverse reaction reports list constipation as a commonly observed side effect. This is due to the medicine's known anticholinergic properties, which can influence the function of the gastrointestinal tract.

Q: Is the effect of DA Cyclizine HCl dose-dependent?

Yes, the effect is considered dose-dependent, which means the amount taken relates to the expected effect. This is reflected in the official guidelines, which specify different maximum daily doses for adults and for pediatric use.

Q: What is the standard regulatory status of DA Cyclizine HCl (e.g., Schedule 4)?

Cyclizine is generally regarded as a non-scheduled medicine in major jurisdictions and is not typically listed as a controlled substance. Furthermore, the World Health Organization (WHO) recognizes it as an Essential Medicine.

Q: Are there different brand names for DA Cyclizine HCl that people should know about?

Yes, the active ingredient cyclizine is marketed globally under various brand names. These names differ depending on the manufacturer and the country where the medicine is sold.

How to Store and Dispose of Cyclizine Hydrochloride

Cyclizine hydrochloride must be stored according to specific regulatory requirements to maintain product stability and ensure safety.

Official Storage Requirements

The medication must be stored below 25 C. To maintain its quality, the product must be kept in the outer carton in order to protect from light. As a mandatory safety measure, Cyclizine HCl must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Cyclizine HCl should not be disposed of via wastewater or household waste. Disposal must be managed in accordance with local requirements and by asking a pharmacist for proper guidance on how to throw away the medicine.